Leap 7902-005

For patients with select solid tumors who have been previously treated

Efficacy and Safety of Pembrolizumab Plus Lenvatinib in Previously Treated Participants With Select Solid Tumors

The purpose of this study is to determine the safety and efficacy of combination therapy with pembrolizumab (MK-3475) and lenvatinib (E7080/MK-7902) in participants with triple negative breast cancer (TNBC), ovarian cancer, gastric cancer, colorectal cancer (CRC), glioblastoma (GBM), or biliary tract cancers (BTC). Participants will be enrolled into initial tumor-specific cohorts which will be expanded if adequate efficacy is determined.

Status:

Recruiting

Phase 2 Icon

Trial Phase

The investigational drug is being studied in a group of patients to see if it is safe and effective.

Eligibility

About the Trial

All patients who enroll* in the trial will receive medication while on the study.

  • 100% will receive pembrolizumab in combination with Lenvatinib

* Patients must have a confirmed diagnosis with advanced cancer in one of six solid tumors and meet all other eligibility criteria to enroll in the trial.

Trial Purpose
9

US Trial Locations

Clinical trial sites are places such as hospitals or clinics where the trial is being conducted.

See Locations

National Trial Reference Number

NCT03797326 Read More at clinicaltrials.gov

What Can You Do Next?

If you would like to learn about this clinical trial or see if you can participate, you can:

Contact Our Trial Info Center

To learn more, call 1-888-577-8839

Discuss With Your Doctor

Print this page or Email it to your doctor to discuss at your next visit

Tip: To help with understanding of some clinical terms used on the page, select an underlined term to see what they mean.

Eligibility

Only a qualified healthcare professional can determine your eligibility. However, this information may be useful in starting a conversation with your doctor.

Condition

The disease, disorder, syndrome, illness, or injury that is being studied. Conditions may also include other health-related issues, such as lifespan, quality of life, and health risks.
  • Advanced Solid Tumors
  • Triple Negative Breast Cancer
  • Ovarian Cancer
  • Gastric Cancer
  • Colorectal Cancer
  • Glioblastoma
  • Biliary Tract Cancers

Age range

18 — no age maximum

Gender(s)

All

Trial Purpose

The purpose of this study is to determine the safety and efficacy of combination therapy with pembrolizumab (MK-3475) and lenvatinib (E7080/MK-7902) in participants with triple negative breast cancer (TNBC), ovarian cancer, gastric cancer, colorectal cancer (CRC), glioblastoma (GBM), or biliary tract cancers (BTC). Participants will be enrolled into initial tumor-specific cohorts which will be expanded if adequate efficacy is determined.

Important information

Participating in a clinical trial is an important decision. Anyone participating in a trial should know as much as possible about what is being studied, what risks are involved and what potential benefits may be gained before deciding to enroll. If you are interested in participating in a clinical trial, please talk to your doctor first.

Trial Locations

    Location
    Status
  • Duarte, California, United States, 91010
    Recruiting
  • Sacramento, California, United States, 95817
    Recruiting
  • Aurora, Colorado, United States, 80045
    Recruiting
  • Germantown, Tennessee, United States, 38138
    Recruiting
  • Madison, Wisconsin, United States, 53792
    Recruiting
  • New Brunswick, New Jersey, United States, 08903
    Recruiting
  • New York, New York, United States, 10016
    Recruiting
  • Seattle, Washington, United States, 98104
    Recruiting
  • Orlando, Florida, United States, 32806
    Recruiting

How to Learn More

When speaking to your doctor, please have the trial reference number available. You can also call 1-888-577-8839 for more information.

Print or email this page.

Trial reference number

A unique identification code given to each clinical trial registered on clinicaltrials.gov.

Leap number

A unique identification code used by the sponsor to identify a specific trial.
Leap-7902-005

Official title

A description of the clinical trial that the trial sponsor and clinicians use to identify a specific trial and its purpose.
A Multicenter, Open-label Phase 2 Study of Lenvatinib (E7080/MK-7902) Plus Pembrolizumab (MK-3475) in Previously Treated Subjects With Selected Solid Tumors (LEAP-005)

Call 1-888-577-8839 to contact our trial information center

Clinical Trials: Important Information to Consider

There is a lot to consider when deciding whether to participate in a clinical study. Any clinical study includes risks, which the study doctor will review with you. Make sure you understand the risks before participating.